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Increasing Provision of Adolescent Vaccines in Primary
Care: A Randomized Controlled Trial
WHAT’S KNOWN ON THIS SUBJECT: The Centers for Disease
Control and Prevention recommends that health departments in all
50 states deliver AFIX (Assessment, Feedback, Incentives, and eXchange)
consultations to 25% of federally funded vaccine providers each year.
AFIX effectively raises vaccination coverage among young children.
WHAT THIS STUDY ADDS: AFIX consultations achieved short-term
gains in coverage for 11- to 12-year-olds for vaccines in the
adolescent platform. No gains occurred for older adolescents or
over the long term. Consultations were equally effective when
delivered in-person or by webinar.
abstract
OBJECTIVES: To assess the effectiveness of in-person and webinar-
delivered AFIX (Assessment, Feedback, Incentives, and eXchange) con-
sultations for increasing adolescent vaccine coverage.
METHODS: We randomly assigned 91 primary care clinics in North
Carolina, serving 107 443 adolescents, to receive no consultation or an
in-person or webinar AFIX consultation. We delivered in-person consulta-
tions in April through May 2011 and webinar consultations in May
through August 2011. The state’s immunization registry provided vaccine
coverage data for younger patients (ages 11–12 years) and older
patients (ages 13–18 years) for 3 adolescent vaccines: tetanus toxoid,
reduced diphtheria toxoid, and acellular pertussis (Tdap); meningo-
coccal; and human papillomavirus (HPV) vaccines ($1 dose, females
only).
RESULTS: At the 5-month follow-up, AFIX consultations increased vac-
cine coverage among younger adolescents. Patients in the in-person
arm experienced coverage changes that exceeded those in the control
arm for Tdap (3.4% [95% confidence interval (CI): 2.2 to 4.6]), menin-
gococcal (4.7% [95% CI: 2.3 to 7.2], and HPV (1.5% [95% CI: 0.3 to 2.7])
vaccines. Patients in the webinar versus control arm also experienced
larger changes for these vaccines. AFIX did little to improve coverage
among older adolescents. At 1 year, the 3 arms showed similar cov-
erage changes. The effectiveness of in-person and webinar consulta-
tions was not statistically different at either time point (all, P ..05).
CONCLUSIONS: Webinar AFIX consultations were as effective as in-person
consultations in achieving short-term increases in vaccine coverage for
younger adolescents. AFIX consultations for adolescents need improve-
ment to have a stronger and more durable impact, especially for HPV
vaccine. Pediatrics 2014;134:e346–e353
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Adolescent vaccines are a cost-effective
way to protect youngpeople fromahost
of vaccine-preventable diseases, but
few adolescents in the United States
receive the full benefit. Only 33% of
adolescent girls complete the 3-dose
human papillomavirus (HPV) vaccine
series, andcoveragehas improved little
in recent years.1 Among adolescents of
both sexes, coverage for tetanus tox-
oid, reduced diphtheria toxoid, and
acellular pertussis (Tdap) and menin-
gococcal conjugate is higher at 85% and
74%, respectively. Even for these vac-
cines, however, uptake varies widely by
state. Geographic disparities, alongwith
plateauing HPV vaccine coverage na-
tionally, suggest an urgent need for
immunization quality improvement.
The experience of early childhood im-
munization suggests that the Centers
for Disease Control and Prevention’s
(CDC) AFIX (Assessment, Feedback,
Incentives, and eXchange) program is
a promising strategy.2,3 Delivered by
state and regional health departments
to vaccine providers, AFIX consists of
a brief consultation in which an im-
munization specialist evaluates a clin-
ic’s vaccine coverage levels and works
with providers to set goals for im-
provement. For early childhood vaccines,
this low-cost strategy of “assessment and
feedback” increases coverage by 4 to 7
percentage points3,4 and has received the
Community Preventive Services Task
Force’s strongest recommendation for
use.5 The CDC supports AFIX programs
in all 50 states, and it encourages health
departments to deliver early childhood
AFIX consultations to at least one-
quarter of federally funded vaccine
providers each year. The existing na-
tional infrastructure for AFIX raises
the possibility that the program could
be used to address underimmunization
among adolescents.
We conducted a randomized controlled
trial with high-volume primary care
clinics in North Carolina to assess the
effectiveness of AFIX consultations in
increasing adolescent vaccine cover-
age. We hypothesized that clinics re-
ceiving in-person AFIX consultations
would have larger increases in cover-
age foradolescent vaccines than clinics
with no consultation. To expand the
program’s potential reach, we also
assessed whether AFIX consultations




Eligible clinics were identified by using
the North Carolina Immunization Regis-
try, an online tracking system used by
94% of the 1201 health care facilities in
the state’s publicly funded vaccine pro-
gram. In 2011, an estimated 67%of North
Carolina adolescents had at least 2 vac-
cine doses documented in the registry.6
We identified pediatric and family prac-
tice clinicswith.200 patients ages 11 to
18 years with active records in the reg-
istry; as recommended by the CDC, we
targeted high-volume clinics tomaximize
program reach. One author (A.M.G.)
randomly ordered and assigned 481 el-
igible clinics to 1 of 3 study arms by
using a 1:1:1 ratio. For each arm, we
selected the first 30 to 31 clinics, yielding
91 clinics in total or the number that
many state health departments could
reach in the study period (Fig 1). Thus,
this study is a pragmatic clinical trial.7 It
had power to detect a change in vaccine
coverage of ∼2 percentage points,
which we considered adequate given
that AFIX consultations have been
shown to increase early childhood
vaccination by 4 to 7 percentage points.3,4
The North Carolina Division of Public
Health institutional review board ap-
proved the study.
Procedure
Our intervention has been described
in detail elsewhere,8 but briefly, each
clinic received 1 in-person AFIX con-
sultation (delivered April–May 2011), 1
AFIX consultation by webinar (delivered
May–August 2011), or no consultation.
During the consultation, which con-
sisted of a single 60- to 90-minute ses-
sion, an immunization specialist (A.M.D.)
met with the nurse who served as the
clinic’s designated vaccine coordinator
to evaluate vaccine coverage.
In the “assessment and feedback”
component of the consultation, the im-
munization specialist presented coor-
dinators with separate coverage
estimates, specific to their clinic, for each
of the following vaccines: Tdap; menin-
gococcal conjugate; 1 and 3 doses of HPV
vaccine (female patients only); 2 doses of
measles-mumps-rubella (MMR); 3 doses
of hepatitis B virus (HBV); and 2 doses of
varicella. In the “exchange” component,
the specialist helped coordinators gauge
their progress by sharing information
about average vaccine coverage for
their clinic’s county as well as cover-
age attained by other clinics within the
county.
In the “incentives” component, the
specialist provided training in immu-
nization best practices. Topics included
how to maintain records in the immu-
nization registry, how to use the registry
to generate reminders for patients
overdue for vaccination, and how to
decrease missed opportunities for con-
comitant vaccination. After completing
an evaluation of the clinic’s current
strengths and weaknesses, the vac-
cine coordinator selected several goals
from a list of 20 prespecified immuni-
zation best practices on which to focus
improvement efforts. At the 5-month
follow-up, the specialist presented co-
ordinators with updated vaccine cover-
age estimates so that they could assess
their progress.
Webinar AFIX consultations used the
samecontent andone-on-oneapproach
as in-person consultations, except that
the immunizationspecialist communicated
with vaccine coordinators via Adobe
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Connect (Adobe Systems Incorporated,
San Jose, CA). This interactive conferenc-
ing platform included a screen-sharing
function that allowed coordinators to
practice registry manipulation.
Measures
Weassessed vaccination status of 11- to
12-year-old and 13- to 18-year-old
patients at 5-month and 1-year follow-
up. Patients were stratified according
to age because 11- to 12-year-olds
constitute the target age for routine
administration of adolescent vaccines,
whereas 13- to 18-year-olds are eligible
for catch-up vaccination. Data were
extracted from the North Carolina Im-
munization Registry by using the CDC’s
Comprehensive Clinic Assessment
Software Application.9 For each age
group, we assessed the number who
had received vaccines in the adoles-
cent platform: Tdap, meningococcal,
and HPV series initiation and completion
($1 dose and 3 doses, female patients
only). We also assessed the number who
received 3 childhood vaccines adminis-
tered to adolescents on a catch-up basis:
HBV (3 doses), MMR (2 doses), and var-
icella (2 doses). The registry also pro-
vided data on how many patients were
up-to-date on all 4 of the following
vaccines: Tdap, meningococcal, HBV
(3 doses), andMMR (2 doses). The CDC’s
Comprehensive Clinic Assessment Soft-
ware Application calculated missed op-
portunities (ie, instances in which a
patient received a vaccine without re-
ceiving 1 of the 4 recommended vac-
cines listed earlier).
The registry was then used to assess
vaccinecoverageatbaseline separately
for the 5-month and 1-year patient
populations. We established study pop-
ulations at the follow-up time points to
include patientswho joined study clinics
during the evaluation period.
The registry provided data on clinic
characteristics, including total number
of adolescent patients; the proportions
of adolescent patients who were black,
white, or another race; the proportions
of male and female patients; and the
proportions of publicly versus privately
funded vaccine doses. Publicly funded
doses were those funded by Vaccines
for Children, a program that provides
freevaccines tovulnerablepopulations,
including uninsured and Medicaid-
eligible youth.10 The registry also pro-
vided data on clinic specialty (pediatric
or family practice) and location. We
defined clinics located within a metro-
politan statistical area as “urban or
suburban” and others as “rural.”11
Statistical Analyses
To assess whether study arms had
different clinic-level characteristics, x2
tests and analysis of variance models
were used. To analyze intervention
effects at the level of the patient, we
performed mixed-level Poisson regres-
sions for each vaccine, modeling the
change in vaccine coverage between
baseline and follow-up for each age
group. Models included a random in-
tercept to account for unobserved het-
erogeneity among clinics as well as an
offset variable equal to the log of the
number of adolescent patients at each
clinic. Because trial arms differed on
proportion of publicly funded vaccine
doses, we controlled for that variable.
FIGURE 1
Flow diagram.
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Using planned contrasts, we compared
coverage changes for each intervention
arm versus the control arm as well as
the intervention arms versus each other.
The primary study outcome was 5-
month coverage change for Tdap, me-
ningococcal vaccine, and HPV vaccine
initiation ($1 dose, female patients only).
We also analyzed coverage changes for
other vaccines at 5 months and for all
outcomes at 1 year.
A sensitivity analysis was performed to
examine whether potential seasonal
differences in vaccination rates affected
findings for theprimarystudyoutcomes.
Due to scheduling constraints, study
arm activities occurred during different
months. We collected 5-month follow-up
data for clinics in the control arm in July
to September 2011, for clinics in the in-
person consultation arm in September
and October 2011, and for clinics in the
webinar arm in October 2011 to January
2012. To further isolate the effect of the
intervention, we repeated our analyses
forkeyfindingsbyusingonlyclinicsfrom
the control arm and the in-person arm
that fell in the overlapping assessment
period.
Vaccine coverage data at follow-up are
reported as unadjusted proportions.
Vaccine coverage changes are reported
as differences in proportions, adjusted
for publicly funded vaccine doses and
accounting for clustering of data ac-
cording to clinic. Data were analyzed by
using SAS version 9.3 (SAS Institute, Inc,
Cary, NC); regression analyses used the
NLMIXED procedure. All statistical tests
were 2-tailed with a critical a of 0.05.
RESULTS
Clinic Characteristics
All 91 clinics selected to be in the
study completed AFIX consultations as
assigned and had accessible data for 5-
month vaccine coverage assessments.
At 5months, study clinics served107 443
adolescents ages 11 to 18 years
(Table 1). Clinic specialties were pri-
marily pediatrics (58%) or family medi-
cine (41%). Themeanproportionofpublicly
funded vaccine doses was higher at
clinics that received no AFIX consulta-
tion (53%; SD: 0.18) than at clinics that
received in-person (42%; SD: 0.21) or
webinar (42%; SD: 0.18) consultations
(P , .05). Intervention arms did not
statistically differ on other character-
istics. At 1 year, 90 of 91 clinics had ac-
cessible data; the webinar arm lost 1
clinic to follow-up because of closure.
Coverage Change at 5 Months
Among adolescents ages 11 to 12 years,
AFIX consultations increased coverage
for the 3 vaccines in the adolescent
platform at 5 months (Table 2, Fig 2).
Patients served by clinics in the in-
person arm had coverage changes
that exceed those in the control arm for
TABLE 1 Clinic Characteristics
Characteristic Control Condition (30 Clinics) In-person Training (30 Clinics) Webinar Training (31 Clinics) P
N (%) N (%) N (%)
Clinic specialty
Pediatric 19 (63) 16 (53) 18 (58) .73
Family practicea 11 (37) 14 (47) 13 (42)
Clinic location
Urban/suburban 22 (73) 25 (83) 22 (71) .49
Rural 8 (27) 5 (17) 9 (29)
Adolescent patient load
#500 patients 13 (43) 10 (33) 11 (35)
501–1500 patients 9 (30) 15 (50) 14 (45) .60
.1500 patients 8 (27) 5 (17) 6 (19)
Mean Proportion (SD) Mean Proportion (SD) Mean Proportion (SD)
Race of adolescent patientsb
White 0.50 (0.25) 0.47 (0.25) 0.52 (0.23) .73
Black 0.30 (0.21) 0.23 (0.22) 0.22 (0.22) .31
Other 0.04 (0.04) 0.03 (0.04) 0.03 (0.04) .60
Not specified 0.16 (0.11) 0.27 (0.23) 0.23 (0.18) .08
Gender of adolescent patients
Male 0.47 (0.03) 0.46 (0.06) 0.47 (0.04) .53
Female 0.48 (0.03) 0.46 (0.06) 0.47 (0.05) .44
Not specified 0.06 (0.04) 0.08 (0.08) 0.06 (0.07) .34
Vaccine dose funding
Private 0.47 (0.18) 0.58 (0.21) 0.58 (0.18) .04
Public 0.53 (0.18) 0.42 (0.21) 0.42 (0.18) .04
The study conditions included 35 569 patients in the control arm, 33 482 patients in the in-person arm, and 38 392 patients in the webinar arm.
a Includes 1 internal medicine practice.
b Race/ethnicity information came from health care providers (rather than from patients or parents). This variable is not among the registry’s required fields, resulting in a higher proportion
of missing data than for other variables.
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Tdap vaccine (3.4% [95% confidence
interval (CI): 2.2 to 4.6]), meningococcal
vaccine (4.7% [95% CI: 2.3 to 7.2]), and
HPV vaccine initiation (1.5% [95% CI: 0.3
to 2.7]). Patients served by clinics in the
webinar versus control arms also had
larger coverage increases for Tdap
vaccine (3.6% [95% CI: 2.4 to 4.9]), me-
ningococcal vaccine (4.4% [95% CI: 2.0
to 6.8]), and HPV vaccine initiation (1.9
[95% CI: 0.7 to 3.1]). For other vaccines,
the webinar arm had larger coverage
changes for varicella vaccine only
(1.8% [95% CI: 0.8 to 2.8]). There was no
evidence of an intervention effect for
HPV vaccine series completion, MMR
vaccine, or HBV vaccine. Comparing the
intervention arms with each other, we
found a statistically significant differ-
ence for varicella vaccine only, which
experienced a higher coverage change
among clinics in the webinar arm
(1.2% [95% CI: 0.2 to 2.3]).
Among adolescents ages 13 to 18 years,
AFIX consultations increased vaccine
coverage at 5 months only for the in-
person versus control arms for HPV
vaccine series completion (0.7% [95% CI:
0.1 to 1.3]). Comparing the intervention
arms with each other, we found no evi-
denceof statistically significant coverage
changes for any vaccine (all, P. .05).
Missed Opportunities for
Vaccination at 5 Months
Among 11- to 12-year olds, changes in
combined coverage for 4 vaccines
(Tdap, meningococcal, HBV, and MMR)
were higher for clinics that received in-
person consultations (3.8% [95% CI: 1.6
to 6.0]) andwebinar consultations (3.8%
[95% CI: 1.6 to 6.0]) compared with the
control arm. For patients in the webinar
arm, missed opportunities also in-
creased more than for those in control
clinics (1.5%[95%: 0.3 to2.7]). Among13-
to 18-year-olds, neither interventionwas
associated with combined coverage
changes or missed opportunities com-
pared with the control arm.
Sensitivity Analysis of
Time-Matched Clinics at 5 Months
The sensitivity analysis identified 9
clinics in the in-person consultation arm
(n = 2489) and 9 clinics in the control
arm (n = 2961) assessed during the
TABLE 2 Vaccine Coverage at 5 Months














% 95% CI % 95% CI
Tdap
Control 84.9 4.2 Ref — — 79.1 3.4 Ref — —
In-person 90.4 7.6 3.4 2.2 to 4.6 ,.001 80.7 3.5 0.1 –0.9 to 1.0 .88
Webinar 92.5 7.8 3.6 2.4 to 4.9 ,.001 80.2 3.1 20.4 –1.3 to 0.5 .41
Meningococcal
Control 53.8 7.6 Ref — — 71.5 4.0 Ref — —
In-person 62.1 12.4 4.7 2.3 to 7.2 ,.001 72.4 4.7 0.7 –0.5 to 2.0 .25
Webinar 59.6 12.0 4.4 2.0 to 6.8 ,.001 65.9 4.8 0.8 –0.5 to 2.1 .21
HPV ($1 dose)a
Control 32.3 3.5 Ref — — 59.8 3.5 Ref — —a
In-person 29.0 4.9 1.5 0.3 to 2.7 .02 61.5 3.9 0.4 –0.7 to 1.5 .49
Webinar 31.1 5.3 1.9 0.7 to 3.1 ,.01 57.7 3.4 20.1 –1.2 to 0.9 .81
HPV (3 doses)a
Control 11.0 1.8 Ref — — 35.2 1.9 Ref — —
In-person 11.3 1.9 0.1 –0.5 to 0.7 .65 40.9 2.6 0.7 0.1 to 1.3 .03
Webinar 11.0 2.0 0.2 –0.3 to 0.8 .42 38.5 2.4 0.5 –0.1 to 1.1 .10
MMR (2 doses)
Control 82.3 0.0 Ref — — 79.3 0.1 Ref — —
In-person 81.9 0.0 0.0b — — 77.0 0.1 0.0b — —
Webinar 86.3 0.1 0.0b — — 80.3 0.1 0.0b — —
HBV (3 doses)
Control 87.2 0.0 Ref — — 82.8 0.1 Ref — —
In-person 85.6 0.0 0.0b — — 79.9 0.1 0.0b — —
Webinar 89.7 0.1 0.0b — — 81.8 0.1 0.0b — —
Varicella (2 doses)
Control 67.4 1.2 Ref — — 51.1 1.1 Ref — —
In-person 67.0 1.8 0.5 –0.1 to 1.1 .09 52.6 1.2 0.1 –0.3 to 0.6 .61
Webinar 71.4 3.0 1.8 0.8 to 2.8 ,.01 55.6 1.5 0.4 –0.1 to 0.9 .10
Intervention arms had different coverage changes only for varicella vaccination among 11- to 12-year-olds (1.2% [95% CI: 0.2 to 2.3]).
Vaccine coverage is unadjusted. Vaccine coverage change and difference from control are adjusted for publicly funded vaccine doses and account for clustering by clinic. Dashes (–) indicate
empty cells related to reference categories or suppressed data.
a HPV coverage assessed only for female 11- to 12-year-old patients (n = 14 994) and 13- to 18-year-old patients (n = 35 375).
b CIs and P values for difference estimates suppressed due to small cell sizes.
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same 1-month time period. Using this
subsample, an analysis of 11- to 12-
year-olds found associations consis-
tent with the primary analysis for 2 of
the 3 vaccines assessed. Adolescents
in the in-person versus control arms
experienced coverage changes that
approached statistical significance
for Tdap vaccine (1.9% [95% CI: –0.1 to
3.9]; P = .064) and HPV vaccine initia-
tion (2.6% [95% CI: 0 to 5.3]; P = .053).
The intervention effect for meningo-
coccal vaccine was no longer statisti-
cally significant (0.8% [95% CI: –8.8 to
10.3]; P = .863).
Coverage Change at 1 Year
At 1 year, the in-person and webinar
armsshowednostatistically significant
coveragechangesrelative to thecontrol
arm for the primary study outcomes
(Fig 2) or other vaccines (Supplemen-
tal Table 3) in either age group. Statis-
tically significant differences between
the intervention arms occurred when
comparing 11- to 12-year-old patients
in the webinar arm versus the in-person
arm for varicella vaccine (1.5% [95% CI:
0.0 to 2.9]). No other comparisons of the
intervention arms were statistically
significant (all, P . .05).
DISCUSSION
In this pragmatic, randomized con-
trolled trial in North Carolina primary
care clinics, we found that in-person
and webinar AFIX consultations im-
proved adolescent vaccine coverage at
FIGURE 2
Vaccine coverage changes among adolescents ages 11 to 12 years at the (A) 5-month and (B) 1-year follow-up. Error bars show 95% CIs.
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5-months postintervention for 11- to 12-
year-olds. For these adolescents, the
intervention arms achieved relative
increasesof 3 to 4percentagepoints for
Tdap vaccine, 4 to 5 percentage points
for meningococcal vaccine, and 2 per-
centage points for HPV vaccine initia-
tion. These incremental improvements
are similar to those attained in early
childhood AFIX programs, but unlike
previous studies, we did not find that
such differences persisted over time.3
At 1 year, vaccine coverage levels in the
intervention arms were similar to the
control arm. This finding may indicate
that vaccine providers in the in-
tervention arms were able to initiate,
but not sustain, quality improvement
efforts. Alternatively, by increasing use
of strategies such as reminder/recall,
the intervention may have prompted
parents in favor of adolescent vacci-
nation to seek such services earlier
than they otherwise would have. AFIX
strategies may have done less to change
the behavior of parents whose decision-
making centered on whether, rather
than when, to get adolescent vaccines.
In contrast to routine vaccination, AFIX
consultationsdidnot improveprovision
of “catch-up” doses at either time
point. Among older adolescents, the
intervention did little to change cover-
age with adolescent vaccines. Further-
more, except in the case of varicella
vaccine, we found no intervention effect
with regard to childhood vaccines
among either age group, even though
unvaccinated adolescents were eligible
for catch-up doses. These findings sug-
gest that, although the intervention was
successful in supporting routine vacci-
nation, the trainings did not prompt
providers to thoroughly review patients’
records for missed vaccines.
Taken together, our findings suggest
several areas in which further in-
tervention development and evaluation
are needed, especially as AFIX for ado-
lescents is already being disseminated
nationally. First, given that intervention
effectiveness waned after 5 months,
clinics may benefit from “booster”
quality improvement sessions designed
to reinforce the intervention. Expanding
the follow-up feedback session, in which
vaccine providers receive updated cov-
erage estimates, to evaluate improve-
ments in light of national benchmarks
may be an especially promising ap-
proach. As assessing clinics’ vaccination
coverage by using immunization regis-
tries becomes easier, providing more
frequent feedback sessions may also
become increasingly possible. Second,
because AFIX consultations achieved
smaller gains in HPV vaccine coverage
comparedwith Tdap andmeningococcal
vaccines, future iterations of the pro-
gram should seek specifically to em-
phasize HPV vaccination. Finally, the AFIX
program must be improved with regard
to catch-up vaccination, and emphasiz-
ing procedures such as chart review
may be particularly effective in this
regard. By developing AFIX in these key
areas, program planners may be suc-
cessful in sustaining the short-term
gains achieved in this study, while also
extending the benefits of AFIX to older
adolescents.
Wewereencouragedtofindthatwebinar
and in-person AFIX consultations offered
similar effectiveness. This finding sug-
gests that an interactive webinar is
a viable way to deliver AFIX without in-
curring travel costs. In a separate pro-
cess evaluation,8 we calculated the cost
of delivering our intervention as $152
per clinic for in-person consultations
versus $100 per clinic for webinar
consultations. Future studies should
seek to replicate our findings in the
context of early childhood AFIX because
webinar delivery could significantly im-
prove the efficiency of this nationally
implemented program.
Study strengths include a strong study
design, a large sample size, and the use
of a provider-based immunization reg-
istry to assess vaccine coverage. Al-
though the completeness and accuracy
of registry data have not been well
studied, our estimates of vaccine cov-
erage among older adolescents at
baseline are in linewith state estimates
derived from the 2011 National Immu-
nization Survey–Teen for Tdap (77% vs
78%), meningococcal conjugate (66%
vs 66%), and HPV vaccine initiation
(57% vs 54%).12 This correspondence
between National Immunization Sur-
vey–Teen and our own findings lends
support to the quality of our data for
adolescent vaccination. However, reg-
istry records likely underestimate
coverage for early childhood vaccines,
such as MMR, which were most often
administered before the establishment
of the registry and documented after
the fact.
Limitations to the present study include
the sequential, rather than simulta-
neous,deliveryof interventionsbystudy
condition. Anecdotal evidence suggests
that summer months elicit a peak in
adolescent vaccination rates, which
may have augmented or diminished the
interventioneffectswereport. Although
our sensitivity analysis and the local-
ized pattern of our findings support an
intervention effect, our results may
reflect the timing of intervention de-
livery rather than, or in addition to,
improved vaccine provision. Because
our sample was restricted to primary
care clinics with more than 200 ado-
lescent patients with active registry
records, replication of ourfindingswith
smaller clinics, those with specialties
other thanpediatric or familymedicine,
or those that do not use an electronic
immunization registry is necessary.
CONCLUSIONS
Implemented in all 50 states,13 CDC’s
AFIX program is well known as an
evidence-based quality improvement
strategy for increasing vaccine cover-
age among young children. This study
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provides early evidence to suggest that
AFIX consultations, whether delivered
in person or by interactive webinar,
may also be effective in raising vaccine
coverage levels among adolescents.
However, improvements in the in-
tervention are first required to sustain
and extend the short-term gains in
vaccine coverage achieved in this
study. Given that the national in-
frastructure needed to support pro-
gram implementation already exists,
widespread dissemination of a modi-
fied AFIX program represents a unique
opportunity to address geographic
disparities in adolescent vaccination
as well as the lackluster uptake of HPV
vaccine nationally. To capitalize on this
opportunity, future studies should seek
to better understand which of the AFIX
quality improvement strategies are
most effective for increasing adoles-
cent vaccine coverage, while continu-
ing to explore approaches, such as
webinar delivery, for maximizing pro-
gram efficiency. In the long term, un-
derstanding how AFIX compares with
other evidence-based strategies, such
as centralized reminder/recall,14–16
will also be important for helping
state health departments allocate
limited funds for immunization quality
improvement.
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